Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial | Charles Explorer

Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial

Publication at Faculty of Physical Education and Sport |

2007

Abstract

angioplasty, anticoagulants

Person